Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01353222
Show Display Options
Rank Status Study
1 Active, not recruiting DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Condition: Urothelial Carcinoma
Interventions: Biological: DN24-02;   Other: Standard of Care

Indicates status has not been verified in more than two years